Browse the evidence

Electromagnetic resistance devices (including variable resistance and eccentric overload settings) produce myoelectric activity (sEMG) amplitudes that are statistically similar to traditional dumbbell resistance training, with observed differences being modest (~5-10%) and of minimal practical significance for muscle excitation.

If you are using or considering an electromagnetic resistance device (like Tonal) with variable or eccentric overload settings, you can expect muscle activation levels that are largely comparable to using dumbbells. While there may be slight differences in shoulder (deltoid) or forearm (brachioradialis) activation, the primary arm muscle (biceps) receives similar stimulation from both. You do not need to switch to dumbbells to get results, nor do you need to buy expensive tech to get better results than dumbbells offer for this movement.

A one-week complete cessation from resistance training (detraining) at the midpoint of a 9-week program does not enhance hypertrophy, power, or endurance compared to continuous training, and significantly reduces strength gains.

If your goal is maximizing strength and size, do not take a full week off from training. This study shows that one week of complete rest during a training block blunts strength gains without improving muscle size. If you are fatigued, consider a 'deload' with reduced volume or intensity rather than complete cessation.

A poly-metabolite score derived from serum and urine metabolomics can accurately predict and discriminate between high (80% energy) and low/zero (0% energy) ultra-processed food (UPF) intake in free-living populations.

Current dietary self-reporting methods for ultra-processed foods are prone to error and misclassification. This research identifies specific blood and urine metabolite patterns that serve as objective biomarkers for UPF intake. For researchers, these scores improve the accuracy of studying UPF's health impacts. For individuals, it underscores that 'ultra-processed' is a biological reality detectable in the body, not just a label on a package, highlighting the metabolic complexity introduced by industrial food processing.

Urolithin A supplementation (1000 mg/day for 4 weeks) significantly reduces indirect markers of muscle damage (creatine kinase) and ratings of perceived exertion following intense exercise in highly trained male distance runners, facilitating recovery without enhancing actual running performance.

If you are a highly trained male distance runner, taking 1000 mg of Urolithin A daily for 4 weeks may help you recover faster from hard workouts by reducing muscle damage markers and perceived exertion. However, do not expect this supplement to make you run faster in races. It supports recovery, not performance output.

Higher consumption of sugar-sweetened beverages (SSBs) is associated with a greater increase in type 2 diabetes risk compared to artificially sweetened beverages (ASBs).

If you must choose between sugary and artificially sweetened drinks, sugary drinks pose a much higher risk for type 2 diabetes. However, both are associated with increased risk compared to not drinking them. The best choice for diabetes prevention is water or unsweetened beverages.

Obesity should be managed as a chronic, relapsing disease with long-term structured medical interventions (pharmacotherapy, surgery, behavioral therapy) rather than relying on short-term lifestyle changes, mirroring the established management model for Type 2 Diabetes Mellitus (T2DM).

Stop treating obesity as a short-term lifestyle issue. Seek a healthcare provider who recognizes it as a chronic disease. This means expecting long-term management with evidence-based tools like GLP-1 receptor agonists (e.g., semaglutide, tirzepatide), behavioral therapy, and potentially surgery, rather than just being told to 'eat less and move more.'

Combining multiple receptor pathways (e.g., GLP-1/GIP, GLP-1/Amylin, or GLP-1/Glucagon) produces synergistic and superior weight loss compared to monotherapy, representing a historical inflection point in obesity pharmacotherapy.

Obesity is a chronic biological disease requiring physiological treatment, not just willpower. Modern combination therapies (targeting GLP-1, GIP, Amylin, or Glucagon receptors) are significantly more effective than older drugs or lifestyle changes alone, achieving 15-24% weight loss in trials. While access and cost are current barriers, these medications are designed to be used alongside lifestyle modifications to overcome biological forces promoting weight gain. Consult a provider about whether combination receptor agonists are appropriate for your health profile.

In patients with type 2 diabetes, initiating tirzepatide (a dual GIP/GLP-1 receptor agonist) results in significantly greater reductions in HbA1c and body weight compared to initiating injectable semaglutide (a GLP-1 receptor agonist) over a 12-month period, regardless of prior GLP-1 RA exposure.

If you have Type 2 Diabetes and are starting a GLP-1 based therapy, choosing tirzepatide over semaglutide is likely to result in better blood sugar control and more significant weight loss over the first year. This benefit holds true whether you have never used these drugs before or have tried semaglutide previously. The trade-off is managing the weekly injection schedule and potential side effects, but the metabolic gains are statistically superior.

Retatrutide increases the rate of gastrointestinal adverse events (nausea, vomiting, constipation) and hypersensitivity reactions compared to placebo, but does not significantly increase serious adverse events.

Be aware that retatrutide is more likely to cause nausea, vomiting, and constipation than a placebo. However, these are typically not 'serious' adverse events, and the drug does not appear to increase the risk of serious health complications or death compared to no treatment. Monitor your symptoms and communicate with your doctor.

Time-restricted eating (TRE) with a 10-hour window, when combined with caloric restriction, leads to greater lean mass loss compared to caloric restriction alone.

If you use a 10-hour eating window to lose weight, be aware that you might lose more muscle than if you just counted calories without a time limit. To counter this, ensure you are eating enough protein within your 10-hour window, perhaps spreading it out evenly.

Healthy low-carbohydrate diet (HLCD) reduces fecal branched-chain amino acids (BCAAs) and increases unsaturated fatty acids, which are positively associated with fat mass.

HLCD changes your gut environment by lowering BCAAs and increasing unsaturated fats, which are linked to lower fat mass. This suggests that what you eat changes how your gut processes nutrients, aiding fat loss.

Higher acculturation levels moderate the effectiveness of the MyPlate intervention, with the most acculturated participants showing the greatest reductions in waist circumference.

If you are recently immigrated or less acculturated to US food systems, standard MyPlate advice might be less effective for reducing belly fat. You may need more personalized guidance that integrates your traditional healthy foods with US dietary guidelines.

Obesity is primarily caused by a sustained positive energy balance where caloric intake exceeds energy expenditure, driven by biological, behavioral, and environmental factors.

Focus on creating a sustainable energy deficit through modest dietary changes and increased physical activity, while recognizing that biological and environmental factors may make this challenging. Addressing these factors (e.g., sleep, stress, food environment) is crucial for long-term success.

In adults with prediabetes, a high-carbohydrate (50% energy) diet reduces fasting glucose more effectively than a reduced-carbohydrate (35% energy) diet when both are calorie-restricted, despite similar weight loss.

If you have prediabetes, you do not need to severely restrict carbohydrates to improve your fasting blood sugar. A diet providing about 50% of your calories from carbohydrates, focusing on high-fiber foods like whole grains and vegetables, can lower fasting glucose better than a lower-carb diet, provided you are in a calorie deficit. Focus on the quality of carbs (fiber) rather than just cutting them out.

Metabolic bariatric surgery (MBS) procedures, specifically Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), single anastomosis duodenal-ileal bypass (SADI), and biliopancreatic diversion (BPD), provide superior long-term total body weight loss (TBWL) compared to obesity management medications (OMM) and endoscopic bariatric procedures (EBP).

If you are struggling with obesity and lifestyle changes alone have not provided sufficient long-term results, metabolic bariatric surgery (specifically RYGB, SG, SADI, or BPD) offers the highest probability of significant, sustained weight loss. While newer medications (semaglutide, tirzepatide) are excellent short-to-medium term options and comparable to surgery initially, surgery tends to maintain higher efficacy over the long term (3+ years). Consult a specialist to determine if you are a candidate for these procedures, especially if your BMI is >= 40 kg/m2.

Combined exercise and pharmacotherapy significantly reduces systolic and diastolic blood pressure and triglycerides compared to exercise alone, but does not significantly improve fasting glucose, HDL, or LDL.

While adding medication to exercise improves blood pressure and triglycerides, it may not significantly improve fasting glucose or cholesterol levels (HDL/LDL) compared to medication alone. Focus on the weight loss and blood pressure benefits.

The EMP16 combination therapy significantly improves the Fatty Liver Index (FLI) and reduces visceral adiposity index (VAI) more effectively than conventional orlistat, suggesting specific benefits for liver health beyond general weight loss.

If you have fatty liver or high visceral fat, this specific combination pill (EMP16) may offer better liver health improvements than standard orlistat. It significantly reduces the Fatty Liver Index compared to conventional treatments.

The quality and source of macronutrients (e.g., plant-based proteins, unsaturated fats) are more important for long-term health outcomes than the specific macronutrient ratio (low-carb vs. low-fat).

Don't just count macros; focus on the quality of your food. Replace refined carbohydrates and saturated fats with whole grains, vegetables, nuts, and unsaturated fats. This improves long-term health more than just restricting calories.

GLP-1-based therapies (semaglutide, tirzepatide) cause lean mass loss proportional to total weight loss (approx. 15-45%), but this reduction is adaptive and accompanied by improved muscle quality (reduced fat infiltration), resulting in preserved or improved muscle function and strength.

If you are taking a GLP-1 medication like semaglutide or tirzepatide, expect to lose some muscle along with fat. This is normal and proportional to your weight loss. Crucially, these drugs often improve muscle quality by reducing fat inside the muscle, which helps preserve your strength and function. To maximize muscle retention, ensure you are consuming adequate protein and engaging in resistance training if possible.

GLP-1 receptor agonists (e.g., liraglutide, semaglutide) resolve MASH histology primarily through substantial weight loss and improved insulin resistance, rather than direct hepatocyte effects.

GLP-1 agonists like semaglutide and liraglutide are effective treatments for MASH, but their primary benefit comes from the weight loss and metabolic improvements they induce, not a direct 'liver cure.' Expect significant weight loss (often 10-15%+), but also manage expectations regarding side effects like nausea, which are common initially. These drugs resolve MASH in a majority of patients but may not reverse advanced fibrosis as effectively. Consult a specialist to determine if the benefits outweigh the burden of injection and side effects for your specific liver stage.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) produce significant real-world weight loss, but effectiveness is substantially lower than in clinical trials due to high discontinuation rates (20-50%) and suboptimal dosing in routine care.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, but their real-world success depends entirely on sticking with them. Many people stop early due to side effects or cost, leading to less weight loss than seen in trials. To get the best results, you must manage side effects (which often fade) and ensure you can afford the medication long-term. If you adhere to the full dose and stay on the drug, your weight loss can match what is seen in clinical trials.

Combining moderate-to-vigorous exercise with GLP-1 receptor agonist (liraglutide) treatment preserves hip and lumbar spine bone mineral density (BMD) during significant weight loss, whereas GLP-1 RA treatment alone reduces BMD at these sites despite similar weight loss.

If you are using a GLP-1 medication like liraglutide or semaglutide for weight loss, you must incorporate regular exercise to protect your bones. This study shows that while the medication alone might reduce bone density at the hip and spine, adding moderate-to-vigorous exercise (like cycling and circuit training) completely preserves bone density, even when you lose a significant amount of weight. Do not rely on the medication alone for skeletal health.

Personalized Type 2 Diabetes management, which tailors pharmacotherapy to individual phenotypic, clinical, and personal factors, improves medication adherence, patient satisfaction, and health outcomes compared to rigid algorithmic approaches.

Work with your doctor to build a treatment plan that fits your specific health profile (like kidney or heart status) and your personal life (like fear of hypoglycemia or preference for pills vs. injections). This collaborative approach leads to better adherence and fewer complications than following a generic, one-size-fits-all checklist.

Personalized glycemic targets should be less aggressive in older patients or those with reduced life expectancy to minimize hypoglycemia risk and polypharmacy burden.

If you are older or have other serious health conditions, your doctor may aim for a higher blood sugar target to keep you safe from dangerous lows and side effects. This focuses on your quality of life rather than just a number.